Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)
The purpose of this study is to obtain safety and efficacy data using tositumomab or Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Tylenol
- drug : Tositumomab and iodine I 131 tositumomab
- drug : SSKI
- drug : Benadryl
Phase: Phase 2
Ages Eligible For Study:
- Histologically confirmed DLCL CD20+ B cell NHL who have relapsed after chemotherapy or are chemotherapy resistant, without prior history of low grade NHL. The patient must have failed at least one chemotherapy regimen containing an anthracycline or equivalent chemotherapeutic agent. - No anticancer treatment for three weeks prior to the treatment dose of Bexxar (six weeks if Rituximab, nitrosourea or Mitomycin C), and fully recovered from all toxicities associated with prior surgery, radiation, chemotherapy or immunotherapy - An IRB approved signed informed consent - Age greater and or equal to 19 years - Prestudy Karnofsky Performance Status of >= 70% - Acceptable laboratory status within 2 weeks prior to patient enrollment including: - ANC of at least 1,500/mm3, platelet count at least 100,000/mm3, Hct greater than 30% and Hgb greater than 9.0 gm% - Bilirubin less than or equal to 2.0, Creatinine less than or equal to 2.0 - Bone marrow involvement with lymphoma less than 25% (bilateral bone marrow) within 6 weeks of enrollment - Acceptable birth control method for men and women of reproductive potential - Female patients who are not pregnant or lactating